Gene Expression Atlas home | about the project | faq | feedback | blog | das | api | help
FGFR2
REST API REST API
Homo sapiens
FGFR2 is differentially expressed in 353 experiments: 188 organism parts: bone marrow, lung, ... (186 more);, 269 disease states: normal, prostate carcinoma, ... (267 more);, 127 cell types 532 cell lines 41 compound treatments and 77 other conditions.
Synonyms ECT1, CD332, JWS, BEK, TK14, TK25, CEK3, CFD1, KGFR, K-SAM
Orthologs Fgfr2 (Mus musculus)   Fgfr2 (Rattus norvegicus)   FGFR_CIOIN (Ciona intestinalis)   fgfr2 (Danio rerio)   FGFR2 (Gallus gallus)   A7E310_BOVIN (Bos taurus)   htl (Drosophila melanogaster)   btl (Drosophila melanogaster)   fgfr2 (Xenopus laevis)   NP_001003336.1 (Canis familiaris)   (Compare orthologs)
Gene Ontology Term angiogenesis, regulation of multicellular organism growth, plasma membrane, positive regulation of cell division, fibroblast growth factor binding, protein binding, neuromuscular junction development, cytoplasm, regulation of cell proliferation, cell cortex, negative regulation of cell proliferation, positive regulation of cell proliferation, membrane, heparin binding, epidermis morphogenesis, peptidyl-tyrosine phosphorylation, protein tyrosine kinase activity, extracellular region, insulin receptor signaling pathway, cell-cell signaling, fibroblast growth factor receptor signaling pathway, organ growth, multicellular organism growth, synaptic vesicle transport, ATP binding, positive regulation of transcription from RNA polymerase II promoter, integral to plasma membrane, nucleus, receptor activity, nucleotide binding, post-embryonic development, cell fate commitment, positive regulation of cell cycle, protein serine/threonine kinase activity, axonogenesis, protein homodimerization activity, integral to membrane, regulation of smoothened signaling pathway, negative regulation of transcription from RNA polymerase II promoter, cell surface, extracellular matrix, positive regulation of Wnt receptor signaling pathway, organ morphogenesis, morphogenesis of embryonic epithelium, protein kinase activity, digestive tract development, embryonic pattern specification, negative regulation of mitosis, positive regulation of mesenchymal cell proliferation, branching morphogenesis of a nerve, mesenchymal cell differentiation, embryonic organ development, positive regulation of epithelial cell proliferation involved in lung morphogenesis, bone morphogenesis, regulation of smooth muscle cell differentiation, branch elongation involved in salivary gland morphogenesis, epithelial cell proliferation, lung lobe morphogenesis, reproductive structure development, orbitofrontal cortex development, membranous septum morphogenesis, regulation of ERK1 and ERK2 cascade, regulation of osteoblast proliferation, in utero embryonic development, outflow tract septum morphogenesis, bone mineralization, positive regulation of ERK1 and ERK2 cascade, fibroblast growth factor receptor signaling pathway involved in mammary gland specification, prostate epithelial cord elongation, bone development, branching involved in salivary gland morphogenesis, squamous basal epithelial stem cell differentiation involved in prostate gland acinus development, regulation of morphogenesis of a branching structure, lung-associated mesenchyme development, positive regulation of canonical Wnt receptor signaling pathway, otic vesicle formation, branching involved in embryonic placenta morphogenesis, hair follicle morphogenesis, prostate gland morphogenesis, positive regulation of epithelial cell proliferation, lacrimal gland development, branching involved in prostate gland morphogenesis, bud elongation involved in lung branching, regulation of epithelial cell proliferation, odontogenesis, lens fiber cell development, limb bud formation, lung alveolus development, regulation of cell fate commitment, excitatory synapse, gland morphogenesis, pyramidal neuron development, embryonic digestive tract morphogenesis, regulation of branching involved in prostate gland morphogenesis, regulation of osteoblast differentiation, mammary gland bud formation, regulation of fibroblast growth factor receptor signaling pathway, mesenchymal cell differentiation involved in lung development, positive regulation of phospholipase activity, embryonic organ morphogenesis, lateral sprouting from an epithelium, epithelial cell proliferation involved in salivary gland morphogenesis, lung development, inner ear morphogenesis, skeletal system morphogenesis, mesenchymal cell proliferation involved in lung development, positive regulation of cardiac muscle cell proliferation, prostate epithelial cord arborization involved in prostate glandular acinus morphogenesis, positive regulation of MAPKKK cascade, ventricular cardiac muscle tissue morphogenesis, midbrain development, ureteric bud development, epithelial cell differentiation, protein autophosphorylation, protein phosphorylation, ventricular zone neuroblast division, fibroblast growth factor receptor signaling pathway involved in orbitofrontal cortex development, fibroblast growth factor receptor signaling pathway involved in positive regulation of cell proliferation in bone marrow, fibroblast growth factor receptor signaling pathway involved in negative regulation of apoptosis in bone marrow, fibroblast growth factor receptor signaling pathway involved in hemopoiesis, fibroblast growth factor-activated receptor activity
InterPro Term Ig_sub, Immunoglobulin, Tyr_kinase_fibroblast_GF_rcpt, Prot_kinase_cat_dom, Ig-like, Ig_sub2, Ig_I-set, Ig_V-set_subgr, Ser/Thr_kinase_dom, Tyr_kinase_cat_dom, Ser-Thr/Tyr_kinase, Se/Thr_kinase-like_dom
Gene-Disease Assocation PFEIFFER SYNDROME, APERT SYNDROME, CROUZON SYNDROME, SCAPHOCEPHALY, MAXILLARY RETRUSION, AND MENTAL RETARDATION, GASTRIC CANCER, HEREDITARY DIFFUSE; HDGC, BEARE-STEVENSON CUTIS GYRATA SYNDROME; BSTVS, ANTLEY-BIXLER SYNDROME WITHOUT GENITAL ANOMALIES OR DISORDERED STEROIDOGENESIS;, JACKSON-WEISS SYNDROME; JWS, LACRIMOAURICULODENTODIGITAL SYNDROME; LADD, SAETHRE-CHOTZEN SYNDROME; SCS
UniProt Accession P21802, Q9UMB0, Q9UMA9, Q8IXC7, Q9UEH2, Q16888, D3DRD4, D3DRD5, D3DRD6, D3DRD3, D3DRE0, D3DRD9, E7EVR6, E7EVR7, E9PCR0, Q7KZ14, E9PES7, E9PFE7
Search EB-eye ENSG00000066468
Show more properties
Experimental Factors
Organism part

studied in E-GEOD-17189, E-GEOD-803, E-GEOD-15765, E-GEOD-6573, E-GEOD-1577, ... (31 experiments)

3
1
Number of published studies where the gene is over/under expressed compared to the gene's overall mean expression level in the study.

anatomogram

Cell line

studied in E-GEOD-3860, E-GEOD-17482, E-GEOD-5258, E-GEOD-19639, E-GEOD-18005, ... (43 experiments)

Factor Value U/D Experiments
SW480
4
E-MEXP-1014, E-MTAB-37, E-GEOD-18005, E-GEOD-2509
BT474
3
E-MEXP-440, E-MTAB-62, E-MTAB-37
MCF-7
3
E-GEOD-20081, E-GEOD-5823, E-GEOD-19639
A549
2
E-GEOD-6013, E-GEOD-3202
AGS
2
E-MTAB-37, E-GEOD-15460
BT-474
2
E-GEOD-3529, E-GEOD-5823
526 more value(s).


Cell type

studied in E-GEOD-492, E-GEOD-20193, E-GEOD-21668, E-GEOD-3920, E-MEXP-750, ... (59 experiments)

Factor Value U/D Experiments
human embryonic stem cell
3
E-GEOD-20033, E-GEOD-18265, E-GEOD-18147
adipocyte
2
E-AFMX-5, E-TABM-145
induced pluripotent stem cell
2
E-GEOD-18265, E-GEOD-18147
embryonic stem cell
1
2
E-MEXP-930, E-GEOD-2248, E-GEOD-26672
germ cell
1
E-MTAB-25
memory B cell
1
E-MEXP-2360
121 more value(s).


Disease state

studied in E-GEOD-3307, E-GEOD-15960, E-GEOD-2466, E-GEOD-1577, E-TABM-15, ... (77 experiments)

Factor Value U/D Experiments
colon carcinoma
4
E-MTAB-57, E-MTAB-62, E-GEOD-3726, E-MTAB-37
lung adenocarcinoma
4
E-MTAB-37, E-GEOD-2514, E-MEXP-231, E-MTAB-62
prostate carcinoma
2
4
E-GEOD-96, E-MEXP-1327, E-MTAB-62, E-MEXP-2034, E-TABM-26, ... (6 experiments)
glioblastoma
1
3
E-GEOD-4290, E-GEOD-4412, E-MEXP-567, E-MTAB-62
dermatomyositis
2
E-GEOD-5370, E-MTAB-62
alveolar rhabdomyosarcoma
2
E-MTAB-62, E-MEXP-121
263 more value(s).


Compound treatment

studied in E-GEOD-1615, E-GEOD-5824, E-TABM-868, E-MEXP-941, E-MEXP-2645, ... (27 experiments)

Factor Value U/D Experiments
ethanol
2
E-GEOD-3113, E-MEXP-2241
17beta-estradiol
4
2
E-GEOD-2292, E-GEOD-4006
glutamine
2
E-MEXP-1335, E-MEXP-941
chloroguine
1
E-GEOD-5418
valproic acid
1
E-GEOD-1615
5-aza-2'-deoxycytidine + trichostatin A
2
1
E-MEXP-1269
35 more value(s).


Age at diagnosis

studied in E-GEOD-3494, E-GEOD-21653

Factor Value U/D Experiments
82
2
1
E-GEOD-3494
52
2
1
E-GEOD-21653


Agent
studied in E-GEOD-19519

Biopsy tissue
studied in E-GEOD-5851

Biosource provider
studied in E-MTAB-37, E-GEOD-14359, E-GEOD-20559

BioSourceProvider
studied in E-GEOD-19519, E-GEOD-19480

Blood/non-blood meta-groups
studied in E-MTAB-62

Bmngrd
studied in E-GEOD-20194, E-GEOD-16716

Cancer site
studied in E-GEOD-4271

Cell treatment
studied in E-MEXP-1192

Cellular component
studied in E-GEOD-1400

Chromosomal aberration
studied in E-TABM-125

Clinical history
studied in E-GEOD-22097, E-GEOD-19743, E-GEOD-7967, E-TABM-125, E-GEOD-21374, ... (8 experiments)

Clinical info
studied in E-GEOD-19743, E-MTAB-37, E-GEOD-6710, E-MEXP-1251, E-GEOD-2191, ... (10 experiments)

Clinical treatment
studied in E-GEOD-1743, E-GEOD-6532

coriell cell line repository identifier
studied in E-GEOD-19519

Developmental stage
studied in E-GEOD-19743, E-GEOD-1614, E-GEOD-20033, E-MEXP-2359, E-GEOD-4667, ... (6 experiments)

dfs time (months)
studied in E-GEOD-21653

Disease stage
studied in E-GEOD-7463

Disease staging
studied in E-GEOD-19743, E-GEOD-7788, E-GEOD-3325, E-GEOD-2509, E-TABM-147, ... (9 experiments)

Environmental stress
studied in E-GEOD-1643, E-GEOD-1518

Er
studied in E-GEOD-20194, E-GEOD-16716

Estrogen receptor status
studied in E-GEOD-6532, E-GEOD-20194, E-GEOD-16716

Ethnic group
studied in E-GEOD-20194, E-GEOD-16716

family id
studied in E-GEOD-19519

Family relationship
studied in E-MEXP-1425

Genetic modification
studied in E-GEOD-8023, E-MTAB-73, E-MEXP-1482, E-GEOD-7578, E-GEOD-17385, ... (8 experiments)

Genotype
studied in E-TABM-1029, E-MEXP-1996, E-GEOD-2466, E-GEOD-17476, E-GEOD-22593, ... (20 experiments)

Gestation age
studied in E-GEOD-14334

369 groups
studied in E-MTAB-62

4 groups from blood to incompletely diff
studied in E-MTAB-62

96 groups
studied in E-MTAB-62

Growth condition
studied in E-GEOD-5681, E-MEXP-215, E-GEOD-20540, E-GEOD-10315, E-TABM-440, ... (14 experiments)

Her2 fish
studied in E-GEOD-20194, E-GEOD-16716

Her2 ihc
studied in E-GEOD-20194, E-GEOD-16716

Her2 status
studied in E-GEOD-20194, E-GEOD-16716

Histology
studied in E-TABM-234, E-GEOD-16194, E-GEOD-21653, E-TABM-276, E-GEOD-20194, ... (6 experiments)

Individual
studied in E-TABM-325, E-MTAB-197, E-GEOD-974, E-MEXP-2069, E-GEOD-1926, ... (43 experiments)

Infection
studied in E-GEOD-2405, E-GEOD-12108, E-GEOD-12254, E-MEXP-561, E-GEOD-980, ... (6 experiments)

Injury
studied in E-GEOD-19743

Labeling
studied in E-LGCL-5

Lymph node status
studied in E-GEOD-6532

Material type
studied in E-MEXP-455, E-GEOD-9171

Media
studied in E-MEXP-765

15 meta groups
studied in E-MTAB-62

4 meta groups
studied in E-MTAB-62

6 meta groups
studied in E-MTAB-62

Metastasis
studied in E-GEOD-18105

Molecular subtype
studied in E-GEOD-21653

Nbefore
studied in E-GEOD-20194, E-GEOD-16716

Observation
studied in E-TABM-276

organ
studied in E-GEOD-24283

Organism
studied in E-GEOD-7540, E-GEOD-1801, E-AFMX-1, E-GEOD-426, E-TABM-84 ... (5 experiments)

Organism status
studied in E-GEOD-19188

Performer
studied in E-GEOD-2004, E-LGCL-5

Phase
studied in E-GEOD-4888

Phenotype
studied in E-GEOD-7819, E-GEOD-1309, E-GEOD-1493, E-GEOD-21750, E-GEOD-1657, ... (7 experiments)

Population
studied in E-GEOD-4922

Progesterone receptor status
studied in E-GEOD-6532

Protocol type
studied in E-GEOD-22097, E-GEOD-3254, E-GEOD-21837, E-GEOD-19445, E-GEOD-19246, ... (6 experiments)

Replicate
studied in E-GEOD-10797, E-GEOD-17204

RNAi
studied in E-GEOD-12438, E-MEXP-101, E-GEOD-3697, E-MEXP-1857, E-MEXP-2759 ... (5 experiments)

Sample preparation
studied in E-GEOD-16728, E-GEOD-12710

sampleID
studied in E-GEOD-24283

Sampling time point
studied in E-GEOD-19743, E-GEOD-21374, E-GEOD-17400, E-GEOD-18995

Sex
studied in E-GEOD-19069, E-GEOD-2466, E-GEOD-22541, E-GEOD-7307

Stimulation
studied in E-GEOD-11428

stimulus
studied in E-GEOD-22103

Strain or line
studied in E-MEXP-1996, E-TABM-125

Subtype
studied in E-GEOD-24283

Survival time
studied in E-GEOD-3494, E-GEOD-4922, E-GEOD-19188

Tbefore
studied in E-GEOD-20194, E-GEOD-16716

Test result
studied in E-GEOD-1926, E-TABM-276

Treatment
studied in E-GEOD-16837, E-GEOD-19246, E-GEOD-13818, E-GEOD-19815

Treatment code
studied in E-GEOD-20194, E-GEOD-16716

Treatments comments
studied in E-GEOD-20194, E-GEOD-16716

Tumor grading
studied in E-GEOD-4290, E-GEOD-4271, E-TABM-43, E-GEOD-1561, E-GEOD-4922 ... (5 experiments)

Vehicle
studied in E-GEOD-5258

Processing time: 0.382 secs.
 
Gene Expression Atlas 2.0.11.1- 12/23/11 3:09:34 PM